Insmed (INSM) Set to Post Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is anticipated to issue its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.3879) per share and revenue of $499.06 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed’s revenue was up 296.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.70) EPS. On average, analysts expect Insmed to post ($1.60) EPS for the current fiscal year and $0.93 EPS for the next fiscal year.

Insmed Trading Up 1.7%

Shares of NASDAQ:INSM opened at $94.96 on Wednesday. The company’s 50-day moving average price is $113.92 and its 200 day moving average price is $126.65. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Bank of America reaffirmed a “buy” rating and set a $207.00 price target on shares of Insmed in a research note on Monday, October 12th. JPMorgan Chase & Co. cut their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, August 10th. Raymond James Financial set a $173.00 target price on Insmed in a research note on Tuesday, October 20th. Evercore reaffirmed an “outperform” rating and set a $170.00 target price on shares of Insmed in a research note on Friday, August 7th. Finally, Morgan Stanley lowered their target price on Insmed from $218.00 to $213.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $198.91.

Insider Buying and Selling at Insmed

In other news, Director David R. Brennan sold 25,000 shares of Insmed stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. The trade was a 38.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.